GlassScriptPhysician profile
Salma Aziz
NPI 1467447326
$6,351.82
in general payments reported to CMS, 2019-2025
25 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $878 · 2021: $937 · 2022: $1,072 · 2023: $898 · 2024: $558 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,751.56 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,324.22 | 2019-2025 | Viaflow, Citrefix, Prostep |
| Surgenex LLC | $1,126.70 | 2025 | Surmatrix, Pellograft, Surgraft |
| Biotissue Holdings INC. | $928.20 | 2021-2025 | |
| Integra Lifesciences Corporation | $568.61 | 2019-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $416.66 | 2020-2023 | Collagenase Santyl |
| Horizon Therapeutics Plc | $324.75 | 2019-2022 | |
| Bioventus LLC | $203.29 | 2020-2024 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Zimmer Biomet Holdings, INC. | $200.14 | 2020-2022 | |
| Paragon 28, INC. | $199.71 | 2022-2023 | Phantom Metatarsal Shortening |
| Sandoz INC. | $191.23 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $185.97 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.54 | 2020-2023 | Jublia, Arazlo |
| Averitas Pharma INC. | $111.02 | 2023 | Qutenza |
| Pfizer INC. | $95.70 | 2019-2020 | |
| Nevro Corp. | $55.98 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $41.48 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $39.07 | 2021 | |
| Galderma Laboratories, L.P. | $38.67 | 2022-2025 | |
| Misonix INC | $33.99 | 2021 | |
| Ani Pharmaceuticals, INC. | $33.99 | 2025 | Oxistat |
| Acell, INC. | $24.49 | 2020 | |
| Assertio Therapeutics, INC. | $18.66 | 2019 | |
| Incyte Corporation | $17.95 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.05 | 2024 | Nuzyra |
| Mayne Pharma Commercial LLC | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salma Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.